Corvus Pharmaceuticals CRVS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.44M+64.5% | $33.72M+73.9% | $29.75M+70.9% | $26.52M+64.2% | $22.76M+42.2% | ||
| $10.49M+24.0% | $9.25M+13.3% | $9.11M+18.5% | $9.02M+24.5% | $8.45M+19.4% | ||
| $47.93M+53.5% | $42.97M+56.0% | $38.86M+54.9% | $35.54M+51.9% | $31.22M+35.2% | ||
| -$47.93M-53.5% | -$42.97M-56.0% | -$38.86M-54.9% | -$35.54M-51.9% | -$31.22M-35.2% | ||
| -$42.15M-12.6% | -$13.33M+77.5% | -$11.65M+78.6% | -$41.35M-107% | -$37.43M-73.8% | ||
| -$44.17M-6.7% | -$15.28M+75.5% | -$15.08M+73.5% | -$45.14M-99.6% | -$41.4M-66.5% | ||
| -$0.52+45.8% | -$0.50+47.4% | -$0.51+44.6% | -$0.99-125% | -$0.96-88.2% | ||
| -$47.81M-53.6% | -$42.87M-56.1% | -$38.76M-55.0% | -$35.45M-52.2% | -$31.13M-35.5% | ||
| -$47.93M-53.5% | -$42.97M-56.0% | -$38.86M-54.9% | -$35.54M-51.9% | -$31.22M-35.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Corvus Pharmaceuticals profitable?
- Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.
- What is Corvus Pharmaceuticals's earnings per share?
- Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.
- Where does Corvus Pharmaceuticals's income statement data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.